 We want to return to our shareholders. We want to return on the research dollars we spend. Those research dollars are driven by the sales of the products today. And that's why we're investing extensively in new applications of these to demonstrate the downstream benefit. But the deal with society for pharma in general is that there is a period of exclusivity. We get a patent granted by the government, which is a monopoly. But that expires. It expires after 20 years from the invention of the drug.